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Aims: In atrial fibrillation (AF) patients, agez75 years is one of the major risk factors
for stroke. However, it is not clear if an upper limit for the indication to OATexists.
Methods and results: For this reason, we performed a prospective study on 290 AF
patients on OATaged z75 years (median age 82 years, total follow-up period 814 pt/
years) followed by our Anticoagulation Clinic. Seventeen major bleeding events were
recorded (rate 2.1×100 pt/years), 11 of which cerebral (1.35×100 pt/years). The
occurrence of major bleedings was associated with history of previous TIA or stroke
[OR 3.4 (1.1–12.5), p=0.01] and with diabetes [OR 4.4 (1.3–14.7) p=0.01]. We found
a trend to a progressive increase in the rate of bleeding risk with the increase of the
CHADS2 score: patients with score 4–6 showed a rate of 3.4×100 pt/years with
respect to 1.5×100 pt/years of patients with lower score. Number Needed to Harm
(NNH) was calculated in relation to different classes of age (75–89, 80–84,z85 years)
and to CHADS2 score. For patients in CHADS2 score 1–3 NNH remained stable across
the different age classes. Instead for patients in CHADS2 score 4–6, NNH varied among
the 3 groups of ages, reaching a value of 10 in patients ≥85 years.
Conclusion: Our data suggest that: 1) in AF patients older than 75 years with CHADS2
score 1–3 the risk of bleeding is low, 2) in AF patients N85 years with CHADS24–6 the
risk of bleeding is high so that the use of OAT should be highly individualised.
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Table 1 Characteristic of patients
n(%)
Number 290
Male 173
Female 117
Median age (range) years 82 (75–96)
Patients/years 814
Hypertension 177 (61%)
Diabetes 57 (20%)
Dyslipidemia 57 (20%)
Coronary artery disease 64 (22%)
Left ventricular disfunction 71 (24.5%)
History of TIA/stroke 111 (38%)
Peripheral artery disease 36 (12.4%)
CHADS2 score
1 42 (14.5%)
2 83 (28.6%)
3 79 (27.2%)
4 64 (22.1%)
5 18 (6.2%)
6 4 (1.4%)
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Atrial fibrillation (AF) is a strong, independent risk
factor for stroke because it leads to formation and
embolism of thrombi in left atrial appendage. The
prevention of embolism is particularly important
because strokes associated with AF are severely large
and disabling. The antithrombotic therapy is the
mainstay for prevention especially after the finding
that rhythm control is not able to prevent embolism
[1]. The rate of stroke in AF patients widely ranges in
relation to the presence of associated risk factors. The
narrow therapeutic window of warfarin and the
difficulties related to its management raise concerns
on a widespread prescription of this drug [2]. Several
international and national scientific societies [3,4]
have produced guidelines to help physicians to stratify
the risk of stroke according to the presence of
different risk factors. In particular, a score has been
recently proposed and validated to obtain an easy and
practical stratification (CHADS2) [5]. Age is one of the
main risk factors for the occurrence of stroke and has
consistently been considered a critical point in the
different studies. The American College of Chest
Physicians recommends the use of warfarin in all
patients agedmore than 75 years and age over 75 years
is one of the 6 points associated to a high risk in the
CHADS2 score. The number of elderly patients is
progressively increasing and the risk of complications
in AF patientsmay significantly differ according to how
old they are. There are several studies dealingwith the
issue of the bleeding risk in elderly patients on OAT
[6,7] and an increased risk of intracranial, frequently
fatal, bleeding has been reported in these patients [8].
Instead data on the risk of bleeding of very old AF
patients on OATare limited and we do not know if we
should establish un upper limit for the prescription of
OAT. To answer this question, we performed a
prospective study on AF patients on OAT aged from
75 to 96 years, followed by our Anticoagulation Clinic.
During follow-up all bleeding events were recorded
and the risk of different age groups was assessed.
Methods
Patients
We prospectively investigated 290 AF patients re-
ferred for the control of OAT to the Anticoagulation
Clinic of the Azienda Ospedaliero Universitaria
Careggi of Florence. Patients' demographic and
clinical datawere collected. A computerized program
(P.A.R.M.A System; Instrumentation Laboratory,
Milan, Italy) [9] was used for the routinemanagement
of OAT. At each follow-up visit OATwas monitored by
PTexpressed as International Normalized Ratio (INR),determined by capillary blood test (Thrombotest ®,
Nycomed Pharma AS, Oslo Norway, commercialised in
Italy by Sentinel Diagnostic, Milan). During each
follow-up visit INR, dose prescription, hospital admis-
sions, intercurrent illnesses, bleeding and thrombotic
eventswere recorded. Patientswhomissed check-ups
formore than 2months were contacted (personally or
through their family or general practitioner) and the
reason for interrupting treatment monitoring was
recorded. In the case of death, further information
about its cause was requested. When this information
was lacking, national register of causes of death and
autopsy results (if available) were consulted.
Data were censored after the first major compli-
cation, after the cessation of OAT or when the
patient stopped being monitored by our Antic-
oagulation Clinic. The INRs were maintained at the
intended therapeutic range of 2–3.
A software programme was used for the assess-
ment of the quality of anticoagulation by deter-
mining the percentage time spent at different INR
levels [10]. All overanticoagulation episodes (de-
fined as INR ≥6.5) in asymptomatic patients were
recorded and treated with 2 mg vitamin K1 per os
administration.
Outcome measures
The occurrence of all types of bleeding and ischemic
complications was recorded. INR was defined as
temporally related to the adverse event when it was
obtained at the time of the event or during the
preceding 8 days. Bleeding was classified as major
when: fatal, intracranial (documented by imaging),
Table 2 Rate of major bleeding events in relation to age
Age Pt/years Total Cerebral Fatal
Rate(n) RR (95%CI) p Rate(n) RR (95%CI) p Rate(n) RR (95%CI)
75–79 433 1.4 (6) 1 0.4 0.7 (3) 1 0.3 0
80–84 271 2.6 (7) 1.8 (0.3–6.7) 0.3 2.2 (6) 3.1 (0.6–20) 0.6 1.8 (5) NA
85–96 110 3.6 (4) 2.6 (0.5–11) 0.3 1.8 (2) 2.6 (0.2–23) 0.4 0.9 (1) NA
Pt/years = patient/years.
NA = not applicable.
Table 3 Rate of major bleeding events in patients on
OAT in relation to CHADS2 score and related annual
NNHs
CHADS2 score Bleeding risk on OAT
n/pt/years Rate× NNH
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when surgery or transfusion of more than two blood
units were required or when haemoglobin was
reduced by at least 2 g/dL.
Stroke was defined as a syndrome characterized by
rapidly developing clinical symptoms and/or signs of
focal and at times global loss of brain function, lasting
N24 h, and with no apparent cause other than
vascular. Ischemic stroke was defined as a stroke
with either a normal brain CTor evidence of a recent
infarction in the clinically relevant area of thebrain on
a CTor MR scanwithin threeweeks of the event, while
Transient Ischemic Attack (TIA) was diagnosed when
neurological defects lasted b24 h. Peripheral embo-
lism was diagnosed when proved with angiography or
thrombectomy.
The presence of traditional cardiovascular risk
factors and characteristics associated with ischemic
complications in AF was assessed on the basis of
patients' interview, echocardiography and hospital
records. Hypertension was defined in the presence
of blood pressure above 160 mm Hg and/or an
antihypertensive treatment and diabetes was de-
fined according to American Diabetes Association
criteria [11]. Coronary artery disease was defined
on the basis of a history of myocardial infarction or
stable and unstable angina. Impaired left ventricu-
lar function was defined as a recent diagnosis of
congestive heart failure or a fractional shortening
b25% by transthoracic echocardiography.
All patients underwent an electrocardiogram and
transthoracic echocardiography. CHADS2 score [12]
was taken to stratify the risk of stroke. The CHADS2
score ranges from 0 to 6 and is calculated by adding 1
point for each of the following risk factors: recent
congestive heart failure, hypertension, ageN75 years,
or diabetes mellitus, and adding 2 points for having
had a previous stroke or TIA. For the sake of simplicity
the scale was collapsed into high (4,5,6), medium
(2,3), and low risk of stroke (1).100 pt/years
1 2/103 1.9 51
2–3 7/478 1.5 68
4–6 8/233 3.4 29
All 17/814 2.1 60Statistical analysis
The SPSS statistical software package (Statistical
Package for Social Sciences, Chicago USA, softwarefor Windows; version 10.0) was used for data
processing. Data are expressed as median and
range due to their skewed distribution. Preliminary
statistical analysis was performed using Wilcoxon's
signed rank test, or Fisher's exact test (categorical
data). The non parametric Mann–Whitney test was
used for comparison between individual groups. The
independent effect of various possible risk factors,
sex and age were investigated by performing the
incidence rate ratio (RR) [13].
Univariate andmultivariate Cox regression models
was used to ascertain which factors (hypertension,
diabetes mellitus, history of TIA or stroke, heart
failure and coronary artery disease) were significant-
ly associated with risk of bleeding and ischemic
events during follow-up. All odds ratios (OR) are given
with their 95% confidence intervals (CI) and a value of
pb0.05 was chosen for statistical significance.
The relative risk for major bleeds were converted
in annual Number Needed to Harm (NNH) to provide
additional clarity in the risk related with OAT. NNHs
were calculated in the different age group in
relation to CHADS2 score.
Results
From June 1995 to October 2005, among the 736 AF
patients referred to our Anticoagulation Clinic for
the management of OAT, we prospectively followed
up 290 patients over 75 years. Two hundred fifty one
patients were over 75 years at the beginning of OAT
whereas 39 were already on treatment at their 75th
Table 4 Rate of major bleeding events in relation to CHADS2 score
CHADS2 75–79 years 80–84 years 85–96 years
n/pt/years Rate×
100 pt/years
NNH n/pt/years Rate×
100 pt/years
NNH n/pt/years Rate×
100 pt/years
NNH
1–3 5/308 1.6 62 3/195 1,5 65 1/80 1.2 80
4–6 1/126 0.8 126 4/177 2.2 44 3/30 10.0 10
All 6/433 1.4 72 7/271 2.6 39 4/110 3.6 27
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which is the object of this study. Median age at the
end of follow-up was 82 years (76–96) and the total
time of observation was 814 patient years (pt/
years). Characteristics, comorbidity and CHADS2
score of these patients are listed in Table 1.
Patients were assessed for the quality of anticoag-
ulant treatment: time spent within, above and below
the intended therapeutic rangewas 69%, 16%and15%,
respectively. Total mortality rate during follow-up
was 3.2×100 pt/years. Five patients died of cerebral
bleeding (0.6×100 pt/years), 1 patient (0.1×100 pt/
years) had a fatal gastrointestinal bleeding, 13
patients (1.6×100 pt/years) died of heart failure, 3
patients (0.4×100 pt/years) died of cancer, 3 patients
(0.4×100 pt/years) had sudden death, and 1 patient
(0.1×100 pt/years) died of ischemic stroke.
During follow-up 17 major bleeding events were
recorded (rate 2.1×100 pt/years). In particular, 6
patients had gastrointestinal bleeding and 11
patients had cerebral bleeding (rate 1.35×100 pt/
years). Among cerebral bleedings, 9 were sponta-
neous and 2 occurred after trauma. We analysed the
events in relation to the increasing age, and in
particular according to three age classes (75–79,
80–84 and ≥85 years). In Table 2 we have reported
total, cerebral and fatal bleedings in the 3 groups of
age. The rates of total major bleeding events were
1.4, 2.6 and 3.6×100 pt/years in the 3 groups
respectively, but these differences were not statis-
tically significant. No difference was found in
relation to the quality of OAT between patients
with (time spent in, above and below the thera-
peutic range was 69%, 13% and 18% respectively)
and those free from bleeding complications (time
spent in, above and below the therapeutic range
was 69%, 16% and 15%, p=0.7, p=0.2, p=0.5
respectively). The rate of major bleeding events
was similar between patients who started OATafter
the age of 75 years and patients who were already
on treatment at their 75th birthday. The median INR
related to major bleeding events was 2.5 (1.2–8);
10/17 patients had INR b3, 4/17 had INR 3–4 and 3
had INR N5 at the occurrence of bleeding. Bleeding
events occurred a median time of 31 months after
starting OAT (range 3–108 months). No differencewas found in relation to sex. At univariate Cox
analysis the occurrence of major bleeding events
was associated with history of previous TIA or stroke
[OR 3.4 (1.1–12.5), p=0.01]. A trend to a higher risk
of major bleeding was found also in the presence of
diabetes [OR 2.4 (0.7–7.1), p=0.09], whereas no
relation was found with arterial hypertension, heart
failure and coronary artery disease. Cox regression
analysis adjusted for the above reported variables
confirmed that history of previous TIA or stroke [OR
3.6 (1.1–11.6) p=0.03] and the presence of diabe-
tes [OR 4.4 (1.3–14.7) p=0.01] were independently
associated with the risk of major bleeding.
When we examined patients in relation to the
CHADS2 score, we found a trend to a progressive
increase in the rate of bleeding with the increase of
the score. In particular, patients classified as at high
risk (score 4–6) showed a rate of 3.4×100 pt/years
with respect to 1.9 and 1.5×100 pt/years of patients
at low and moderate risk respectively (Table 3). In
Table 3 we have reported the corresponding annual
NNHs. Rates of bleeding and corresponding NNHs
were also calculated in the 3 age groups in relation
to CHADS2 score (Table 4). A trend to an increased
rate of bleedingwas observed in patients aged 80–84
and 85–96 years with CHADS2 score 4–6.
Discussion
To better understand if the risk of complications
varies in the different age groups of elderly AF
patients on OAT, we performed this prospective
study in AF patients over 75 years. The present study
showed that the risk of bleeds is growing in relation
to ageing, as expected. However, our data demon-
strated that the risk is growing also in relation to
CHADS2 score.
Fihn et al. [6] found an increase of fatal and life-
threatening bleeds. The higher risk of fatal bleeding
in elderly patients was especially related to cerebral
haemorrhages [6,8]. In keeping with published data,
in our series there was a high prevalence of cerebral
bleeding in elderly patients, with a high case-
fatality rate. Palareti et al. [7], among patients
over 75 years, reported a rate of cerebral bleedings
of 1.1 per 100 pt/years, a finding similar to ours. As
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19], most bleeding events occurred with INR within
the therapeutic range. Fang et al. [16] found an
increase in intracranial haemorrhages in AF
patients over the age of 85 years; the rate was
increased in particular in those with INRN3.5, but
intracranial haemorrhage did occur also in patients
with subtherapeutic INRs (b2). In agreement with
these data, in our cohort only 3/17 patients with
haemorrhagic complications had INR values N5. In
addition, the quality of anticoagulation control was
not different between patients who did and those
who did not experience bleeding events. Gage et
al. observed that the history of previous stroke was
an independent risk factor for both recurrent
cerebral ischemia and cerebral bleeding (RR 2.2)
and they concluded that prescribing warfarin in AF
patients with high risk for stroke (CHADS2z2) [20]
is cost-effective. The association between prior
stroke and intracranial haemorrhage was reported
by other Authors [21–23] and loss of microvascular
integrity or disruption was the mechanism proposed
to explain this association.
Analysing our data according to age groups and
CHADS2 score, we observed an increased risk of
bleeding not only in relation to ageing, but also to
the increase of the thrombotic risk expressed by the
CHADS2 score. CHADS2 score is an easy-to-use
classification scheme that has been validated [13]
as an useful tool to assess the risk of stroke in elderly
AF patients. The application of this score to our
population allowed us to compare the risk of stroke
with that of bleeding. Although subdivision of
patients in relation to both age groups and CHADS2
score leads to a very low number of bleeding events
in each group, this led us to identify patients
z80 years with CHADS2 score 4–6 as a group at
high risk both for bleeding and ischemic stroke. In
addition, patients older than 85 years with high
CHADS2 score showed an even higher risk (NNH=10).
Therefore, this group of patients is exposed at same
time both to an elevated risk of bleeding and of
stroke. A recent meta-analysis by Lip and Edwards
[24] reports a Number Needed to Treat (NNT) of 16 to
prevent stroke with OAT in AF patients with CHADS2
score 4–6. The comparison of our data with those
available in the literature, with the limitation due to
the absence of a specific analysis on very old
patients, seems to suggest that older AF patients
with CHADS21–3 have a relatively low rate of
bleeding. In particular, low-risk patients with
CHADS21 (no other risk factor than age) show a
NNH of 51. Interestingly, the NNT of CHADS2=1
patients in the quoted meta-analysis [24] is similar
(58) to NNH calculated in our patients. This could
indirectly suggest that older AF patients withCHADS2=1 have relatively low rates of stroke and
may not benefit fromOAT. On the other hand, in very
old patients with CHADS2 4–6 the high risk of both
bleeding and thrombotic events, suggests that the
use of OAT should be highly individualised.
A limitation of this study is the fact that it was
performed in a single centre, with a low statistical
power. In addition, patients were followed up in a
specialised Anticoagulation Clinic which likely con-
tributed to achieve a good anticoagulation control
and to have a low number of bleeding events.
However, our study reflects directly the clinical
practice and patients were unselected differently
from those of clinical trials.
In conclusion, our study performed in very old AF
patients on OAT suggests that the risk of bleeding is
quite low in those with CHADS2 scores 1–3 but it
becomes very high in patients z85 years with
CHADS2 score 4–6. A multicentre study on a larger
population of elderly AF patients would be very
useful to establish if the benefit of OAT persists in
very old patients with high CHADS2 score.References
[1] Wyse DG, Waldo AL, Di Marco JP, Domanski MJ, Rosenberg Y,
Schron EB, et al. A comparison of rate control and rhythm
control in patients with atrial fibrillation. N Engl J Med
2002;347:1825–33.
[2] Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S.
Hemorrhagic complications of anticoagulant treatment.
Chest 2004;126:287S–310S.
[3] Iliceto S. A guide to oral anticoagulant therapy : recom-
mendation of Italian Federation of Anticoagulation Clinics.
Haematologica 2003;88(suppl 2):1.
[4] Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning
WJ. Antithrombotic therapy in atrial fibrillation: the Seventh
ACCP Conference on Antithrombotic and Thrombolytic
Therapy. Chest 2004;126:429S–56S.
[5] Gage BF, Gage BF, van Walraven C, Pearce L, Hart RG,
Koudstaal PJ, et al. Selecting patients with atrial fibrillation
for anticoagulation: stroke risk stratification in patients
taking aspirin. Circulation 2004;110:2287–92.
[6] Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG,
White RH. The risk for and severity of bleeding complica-
tions in elderly patients treated with warfarin. The National
Consortium of Anticoagulation Clinics. Ann Intern Med
1996;124:970–9.
[7] Palareti G, Hirsh J, Legnani C, Manotti C, D'Angelo A, Pengo
V, et al. Oral anticoagulation treatment in the elderly: a
nested, prospective, case-control study. Arch Intern Med
2000;160:470–8.
[8] Hylek EM, Singer DE. Risk factors for intracranial hemor-
rhage in outpatients taking warfarin. Ann Intern Med
1994;120:897–902.
[9] Mariani G, Manotti C, Dettori AG. A computerized regulation
of dosage in oral anticoagulant therapy. Res Clin Lab
1990;20:119–25.
[10] Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A
method to determine the optimal intensity of oral antico-
agulant therapy. Thromb Haemost 1993;69:236–9.
352 D. Poli et al.[11] Report of the expert committee on the diagnosis and
classification of diabetes mellitus. Diabetes Care 2002;26:
S5–20.
[12] Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW,
Radford MJ. Validation of clinical classification schemes for
predicting stroke: results from the National Registry of
Atrial Fibrillation. JAMA 2000;285:2864–70.
[13] Rothman KJ. Epidemiology. Chap. 3. Oxford: Oxford Univer-
sity Press; 2002. p. 46–9.
[14] Landefeld CS, Goldman L. Bleeding in outpatients treated
with warfarin: relation to the prothrombin time and
important remediable lesions. Am J Med 1989;87:153–9.
[15] Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby
JV, et al. Effect of intensity of oral anticoagulation on stroke
severity and mortality in atrial fibrillation. N Engl J Med
2003;349:1019–26.
[16] Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS,
et al. Advanced age, anticoagulation intensity, and risk for
intracranial hemorrhage among patients taking warfarin for
atrial fibrillation. Ann Intern Med 2004;141:745–52.
[17] Poli D, Antonucci E, Lombardi A, Cecchi E, Gensini GF,
Abbate R, et al. Prisco D Management of oral anticoagulant
therapy in the real practice of an anticoagulation clinic:
focus on atrial fibrillation. Blood Coagul Fibrinolysis
2005;16:491–4.
[18] Stroke Prevention in Atrial Fibrillation Investigators. Bleed-
ing during antithrombotic therapy in patients with atrial
fibrillation. Arch Intern Med 1996;156:401–16.[19] Pengo V, Legnani C, Noventa F, Palareti G. ISCOAT Study Group
(Italian Study onComplications ofOral anticoagulantTherapy).
Oral anticoagulant therapy in patients with nonrheumatic
atrial fibrillation and risk of bleeding. A multicentre inception
cohort study. Thromb Haemost 2001;85:418–22.
[20] Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS,
Rich MW. Incidence of intracranial hemorrhage in patients
with atrial fibrillation who are prone to fall. Am J Med
2005;118:612–7.
[21] Hart RG, Boop BS, Anderson DC. Oral anticoagulants and
intracranial hemorrhage. Facts and hypotheses. Stroke
1995;26:1471–7.
[22] Saloheimo P, Juvela S, Hillbom M. Use of aspirin, epistaxis,
and untreated hypertension as risk factors for primary
intracerebral hemorrhage in middle-aged and elderly
people. Stroke 2001;32:399–404.
[23] Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous
system bleeding during antithrombotic therapy: recent data
and ideas. Stroke 2005;36:1588–93.
[24] Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin
and ximelagatran in patients with non-valvular atrial
fibrillation: a systematic review and meta-analysis.
Thromb Res 2006;118:321–33.
